FDA Clearance Tracker · P110033-S091
Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skinvive
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 11, 2026
Approved
Time to decision
582 days
Received Jan 6, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P110033-S091
- Device name
- Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skinvive
- Applicant
- Allergan
- Applicant location
- Irvine, CA
- Received
- Jan 6, 2025
- Decided
- Aug 11, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P110033
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for using the sodium hyaluronate manufactured from HTLs additional manufacturing line (HTL4) as raw materials for Juvéderm products.
Source documents
Other decisions for Allergan
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SKINVIVE by JUVEDERM®PMA supplement
P110033-S099 · Decided Jun 11, 2026 · 394 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.